A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 165 participants.

Also called NCT04945460

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 165 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04945460
  • EU CT 2023-509141-12-00
  • WHO UTN U1111-1309-6433
  • EudraCT 2021-003020-32
Main results
  • Sotatercept for Combined Post- and Precapillary Pulmonary Hypertension Associated With Heart Failure: Results From the Phase 2, Randomized, Placebo-Controlled CADENCE Study Circulation, 2026-05-12 DOI, PubMed 41904795

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Belgium, Canada, France, Germany, Israel, Italy, Mexico, Poland, Spain, Sweden, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04945460. Randomized; triple masking; primary purpose treatment. Start 2021-12-29 (actual); primary completion 2025-09-05 (actual). Results posted on 2026-09-23.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)
Acronym
CADENCE
Condition
Hypertension, Pulmonary
Intervention (Drug)
Sotatercept 0.3 mg/kg
Intervention (Drug)
Placebo
Intervention (Drug)
Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg
Lead sponsor
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA (class: industry)

Record details

Record id
cardio:ct-nct04945460
Content hash
0368e6690cfc36a6c9de638e96010d8e3fa8254b07491aa0e080775785f03ad9